Royalty Pharma plc Annual Nonoperating Income (Expense) in USD from 2018 to 2024

Taxonomy & unit
us-gaap: USD
Description
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Summary
Royalty Pharma plc quarterly/annual Nonoperating Income (Expense) history and growth rate from 2018 to 2024.
  • Royalty Pharma plc Nonoperating Income (Expense) for the quarter ending December 31, 2024 was -$27.2M, a 126% decline year-over-year.
  • Royalty Pharma plc Nonoperating Income (Expense) for the twelve months ending December 31, 2024 was $38.4M, a 81.5% decline year-over-year.
  • Royalty Pharma plc annual Nonoperating Income (Expense) for 2024 was $38.4M, a 81.5% decline from 2023.
  • Royalty Pharma plc annual Nonoperating Income (Expense) for 2023 was $208M.
  • Royalty Pharma plc annual Nonoperating Income (Expense) for 2022 was -$77M, a 59.4% increase from 2021.
Nonoperating Income (Expense), Trailing 12 Months (USD)
Nonoperating Income (Expense), Annual (USD)
Nonoperating Income (Expense), YoY Annual Growth (%)
Period Value YoY Chg Change % Start Date End Date Report Filed
2024 $38.4M -$170M -81.5% Jan 1, 2024 Dec 31, 2024 10-K 2025-02-12
2023 $208M +$285M Jan 1, 2023 Dec 31, 2023 10-K 2025-02-12
2022 -$77M +$113M +59.4% Jan 1, 2022 Dec 31, 2022 10-K 2025-02-12
2021 -$190M -$296M -278% Jan 1, 2021 Dec 31, 2021 10-K 2024-02-15
2020 $107M +$268M Jan 1, 2020 Dec 31, 2020 10-K 2023-02-15
2019 -$162M -$315M -205% Jan 1, 2019 Dec 31, 2019 10-K 2022-02-15
2018 $153M Jan 1, 2018 Dec 31, 2018 10-K 2021-02-24
* An asterisk sign (*) next to the value indicates that the value is likely invalid.